Viridian Therapeutics, Inc.VRDNNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +4.17% | +81958.14% | +83.33% |
| Gross Profit Growth | +0.00% | +0.00% | +4.17% | +81958.14% | -361.11% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +61.13% | +33.13% | +27.78% | +23.13% | +5.94% |
| Weighted Average Shares Diluted Growth | +61.13% | +33.13% | +27.78% | +23.13% | +5.94% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -100.00% | -100.00% | +0.00% | +499900.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +51.38% | +4.85% | -0.57% | -25.23% | +21.15% |
| Book Value per Share Growth | -5.70% | -22.06% | -23.84% | -42.26% | +1.50% |
| Debt Growth | +0.22% | +0.76% | +1.83% | +12.83% | +140.31% |
| R&D Expense Growth | +86.63% | +87.66% | +54.16% | +24.73% | +23.97% |
| SG&A Expenses Growth | -52.77% | +13.83% | +25.83% | +68.81% | +116.08% |